DELIVERING BREAKTHROUGHS
Path to Progress
Novel AAV capsids born from Voyager’s RNA-driven TRACERTM screening platform hold promise to target desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional AAV serotypes. TRACER capsids power internal product development and external partnerships with the goal of elevating the field of gene therapy to its highest potential.1
Equipped for the Journey
We see each step in our journey as progress toward unlocking the full potential of gene therapy. This is an opportunity to evolve, innovate, and close in on this breakthrough that has enormous promise to change the trajectory of disease and positively alter the lives of millions of people.
1 Nonnenmacher, et al. “RNA-driven Evolution of AAV Capsid Libraries Identifies Variants with High Transduction Efficiency in Non-Human Primate Central Nervous System.” ASGCT 2021.
In the News
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Jan. 24, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with two newly hired employees that, among other things, provide for
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
– Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and
